Department of Biological Sciences, Louisiana State University, 202 Life Sciences Building, Baton Rouge, LA, 70803, USA.
Department of Comparative Biomedical Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, LA, USA.
BMC Microbiol. 2020 Jun 1;20(1):140. doi: 10.1186/s12866-020-01816-5.
Respiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infections in infants. There are still no vaccines or specific antiviral therapies against RSV, mainly due to the inadequate understanding of RSV pathogenesis. Recent data suggest a role for gut microbiota community structure in determining RSV disease severity. Our objective was to determine the gut microbial profile associated with severe RSV patients, which could be used to help identify at-risk patients and develop therapeutically protective microbial assemblages that may stimulate immuno-protection.
We enrolled 95 infants from Le Bonheur during the 2014 to 2016 RSV season. Of these, 37 were well-babies and 58 were hospitalized with RSV. Of the RSV infected babies, 53 remained in the pediatric ward (moderate) and 5 were moved to the pediatric intensive care unit at a later date (severe). Stool samples were collected within 72 h of admission; and the composition of gut microbiota was evaluated via 16S sequencing of fecal DNA. There was a significant enrichment in S24_7, Clostridiales, Odoribacteraceae, Lactobacillaceae, and Actinomyces in RSV (moderate and severe) vs. controls. Patients with severe RSV disease had slightly lower alpha diversity (richness and evenness of the bacterial community) of the gut microbiota compared to patients with moderate RSV and healthy controls. Beta diversity (overall microbial composition) was significantly different between all RSV patients (moderate and severe) compared to controls and had significant microbial composition separating all three groups (control, moderate RSV, and severe RSV).
Collectively, these data demonstrate that a unique gut microbial profile is associated with RSV disease and with severe RSV disease with admission to the pediatric intensive care unit. More mechanistic experiments are needed to determine whether the differences observed in gut microbiota are the cause or consequences of severe RSV disease.
呼吸道合胞病毒(RSV)是导致婴儿下呼吸道感染的首要原因。目前仍没有针对 RSV 的疫苗或特效抗病毒疗法,这主要是因为我们对 RSV 发病机制的认识还不够充分。最近的数据表明,肠道微生物群落结构在决定 RSV 疾病严重程度方面发挥着作用。我们的目标是确定与重症 RSV 患者相关的肠道微生物特征,这有助于识别高危患者,并开发可能刺激免疫保护的治疗性保护性微生物组合。
我们在 2014 年至 2016 年 RSV 季节期间从 Le Bonheur 招募了 95 名婴儿。其中 37 名婴儿健康,58 名因 RSV 住院。在感染 RSV 的婴儿中,53 名仍在儿科病房(中度),5 名随后被转至儿科重症监护病房(重度)。在入院后 72 小时内采集粪便样本;通过对粪便 DNA 进行 16S 测序评估肠道微生物群落的组成。在 RSV(中度和重度)与对照组相比,S24_7、梭状芽胞杆菌目、恶臭杆菌科、乳杆菌科和放线菌科明显富集。与中度 RSV 患儿和健康对照组相比,重度 RSV 患儿肠道微生物群落的 alpha 多样性(细菌群落的丰富度和均匀度)略低。与对照组相比,所有 RSV 患儿(中度和重度)的 beta 多样性(整体微生物组成)差异显著,且三组(对照组、中度 RSV 患儿和重度 RSV 患儿)的微生物组成有显著差异。
总的来说,这些数据表明,独特的肠道微生物特征与 RSV 疾病以及需要入住儿科重症监护病房的重度 RSV 疾病相关。需要进行更多的机制实验来确定肠道微生物群中观察到的差异是重度 RSV 疾病的原因还是结果。